Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

JOHNSON & JOHNSON Director's Dealing 2024

Feb 13, 2024

29750_dirs_2024-02-12_3ef6637a-69af-4302-be8a-f2b1234b87d8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2024-02-08

Reporting Person: Taubert Jennifer L (EVP, WW Chair, Pharmaceuticals)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-08 Common Stock M 3739.0000 $0.0000 Acquired 143329.0010 Direct
2024-02-08 Common Stock F 1913.0000 $156.3300 Disposed 141416.0010 Direct
2024-02-09 Common Stock M 59397.0000 $90.4400 Acquired 200813.0010 Direct
2024-02-09 Common Stock S 59397.0000 $156.2700 Disposed 141416.0010 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-08 Restricted Share Units $ M 3739.0000 Disposed Common Stock (3739.0000) Direct
2024-02-09 Employee Stock Options (Right to Buy) $90.4400 M 59397.0000 Disposed 2024-02-09 Common Stock (59397.0000) Direct

Footnotes

F1: Restricted Share Units awarded under Long-Term Incentive Plan on February 8, 2021 with a three year vesting period. The Restricted Share Units converted into shares of Common Stock on a one-for-one basis upon vesting.

F2: Shares withheld for payment of taxes upon vesting of Restricted Share Units.

F3: This transaction was executed in multiple trades at prices ranging from $156.180 to $156.360. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.